Abstract 373P
Background
Head and neck squamous cell carcinoma (HNSCC) is a common cancer worldwide with high mortality rates. Studies suggested the incidence of HNSCC will increase by approximately 30% by 2030. However, elderly patients with advanced HNSCC often face challenges in receiving sufficient treatment because of their lower tolerance to therapy. Exploring different approaches for HNSCC is crucial given the world's aging population.
Methods
The study between 2010 and 2021 involved patients with HNSCC located in the oral cavity, oropharynx, larynx, and hypopharynx. The research was focused on advanced-stage patients aged 70 or older. The data were collected from a cancer registry database at a referral institution. The Kaplan-Meier method was used to estimate overall survival (OS).
Results
The study included 1144 patients with HNSCC, of whom 207 (18.1%) were above 70 years old. Over 50% of the patients had advanced disease without metastasis, being stages III, IVA and IVB. The median OS for geriatric patients with advanced disease was 16.1 months. Patients who underwent curative-intent surgery, radiotherapy, or chemoradiotherapy had better survival rates than those who did not (log-rank test: all p < .01). Furthermore, patients with a higher body mass index (≥ 18.5) had improved OS (p = .03). No significant differences were observed in OS between geriatric patients who received systemic therapy or not. By the multivariate analysis, patients who underwent surgery demonstrated higher survival rates, while those with tumors located in the hypopharynx showed inferior outcomes. The median OS was 29.9 and 8.4 months, respectively (p < .01 and p = .01). Table: 373P
AJCC stage III and IV (M0) head and neck cancer (p < .01)
≥ 70-year-old patients | Number | 3-year survival rate |
Withoout curative surgery | 62 | 22.6% |
With curative surgery | 44 | 45.5% |
Conclusions
Geriatric patients with locally advanced HNSCC have a poor prognosis especially for hypopharyngeal cancer. The study suggests that curative surgery may be a beneficial treatment for these patients. However, further research is warranted to optimize treatments and improve outcomes and quality of life for this vulnerable group.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank all colleagues who contributed to this study. The work was supported by the medical integration database of National Taiwan University Hospital and National Taiwan University Hospital Yunlin branch.
Legal entity responsible for the study
Y.T. Liu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract